JNJ News Friday, June 26, 2026 0.00 Neutral

Johnson & Johnson's TECVAYLI Receives Committee For Medicinal Products For Human Use Approval Recommendation To Treat Relapsed Or Refractory Multiple Myeloma

Johnson & Johnson's TECVAYLI Receives Committee For Medicinal Products For Human Use Approval Recommendation To Treat Relapsed Or Refractory Multiple Myeloma

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day